Legal & General Group Plc Reduces Holdings in Legend Biotech Corporation Sponsored ADR $LEGN

Posted by Geri Gentry on Jun 8th, 2026

Legal & General Group Plc decreased its holdings in shares of Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN – Free Report) by 19.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 226,950 shares of the company’s stock after selling 53,841 shares during the period. Legal & General Group Plc’s holdings in Legend Biotech were worth $4,934,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Suvretta Capital Management LLC raised its position in Legend Biotech by 1.2% during the 3rd quarter. Suvretta Capital Management LLC now owns 3,818,009 shares of the company’s stock valued at $124,505,000 after purchasing an additional 44,000 shares during the last quarter. Artisan Partners Limited Partnership raised its position in Legend Biotech by 20.1% during the 3rd quarter. Artisan Partners Limited Partnership now owns 2,547,952 shares of the company’s stock valued at $83,089,000 after purchasing an additional 425,684 shares during the last quarter. Alliancebernstein L.P. raised its position in Legend Biotech by 4.6% during the 3rd quarter. Alliancebernstein L.P. now owns 1,632,967 shares of the company’s stock valued at $53,251,000 after purchasing an additional 72,371 shares during the last quarter. Millennium Management LLC raised its position in Legend Biotech by 5.0% during the 3rd quarter. Millennium Management LLC now owns 792,485 shares of the company’s stock valued at $25,843,000 after purchasing an additional 37,638 shares during the last quarter. Finally, Canada Pension Plan Investment Board bought a new position in Legend Biotech during the 2nd quarter valued at approximately $15,790,000. Institutional investors own 70.89% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Weiss Ratings lowered Legend Biotech from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday. Morgan Stanley lowered their price target on Legend Biotech from $49.00 to $48.00 and set an “overweight” rating for the company in a research report on Wednesday, May 13th. Jefferies Financial Group reaffirmed a “buy” rating and set a $69.00 price target on shares of Legend Biotech in a research report on Tuesday, March 10th. Rothschild & Co Redburn lowered Legend Biotech from a “buy” rating to a “neutral” rating and set a $24.00 price target for the company. in a research report on Thursday, February 12th. Finally, Royal Bank Of Canada increased their target price on Legend Biotech from $62.00 to $64.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 13th. Eleven research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $60.23.

Get Our Latest Analysis on Legend Biotech

Insider Transactions at Legend Biotech

In other Legend Biotech news, CEO Ying Huang sold 9,936 shares of Legend Biotech stock in a transaction on Wednesday, March 25th. The stock was sold at an average price of $8.77, for a total transaction of $87,138.72. Following the completion of the transaction, the chief executive officer owned 247,438 shares in the company, valued at approximately $2,170,031.26. The trade was a 3.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.02% of the company’s stock.

Legend Biotech Stock Performance

Shares of NASDAQ:LEGN opened at $32.62 on Monday. The stock has a fifty day simple moving average of $24.69 and a two-hundred day simple moving average of $22.42. The stock has a market capitalization of $6.06 billion, a price-to-earnings ratio of -47.97 and a beta of 0.35. Legend Biotech Corporation Sponsored ADR has a 12-month low of $16.24 and a 12-month high of $45.30.

Legend Biotech (NASDAQ:LEGN – Get Free Report) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.01). The company had revenue of $305.10 million for the quarter, compared to analysts’ expectations of $306.51 million. Legend Biotech had a negative net margin of 21.98% and a negative return on equity of 24.92%. The firm’s quarterly revenue was up 56.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.07) EPS. As a group, equities research analysts predict that Legend Biotech Corporation Sponsored ADR will post 0.03 EPS for the current year.

About Legend Biotech

(Free Report)

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.